Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Michael Palladinetti, global head of business development and licensing at Sanofi, told delegates attending Bio Europe Spring in Barcelona, Spain last week that history has shown us time and time again that no one has the monopoly on the next wave of innovation. Citing the recent GLP-1 wave, Palladinetti said the industry has a bit of fear of missing out (FOMO) and paid kudos to Lily and Novo for staying in the space. He added how innovation is also very difficult and that industry players need to have a broad view. Both firms are pioneers in the diabetes space, having launched their own versions of insulin over 100 years ago
How to Check if a Plan Covers GLP-1 Medications While some patients may struggle to get GLP-1 drugs covered, you shouldn't assume the worst
Studies show that while many patients experience substantial weight loss, average results outside of clinical trials can be more modestoften between 5% and 12% of body weight lost, depending on adherence and length of treatment
Since chronic inflammation can block GLP-1 receptors and disrupt gut hormone production, reducing it helps restore your bodys natural ability to produce and respond to GLP-1
Consider consulting a registered dietitian for personalized guidance, especially if you have kidney disease or other conditions requiring dietary modifications
doi: 10.1016/s0925-4773(02)00118-1
